Table 2 Characteristics of studies and patients included in the PFS and OS meta-analysis
Study | Year | Country | Study design | AR-V7 detection assay | Patients characteristics | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Treatment | Patients (n) | Age (range) | Gleason score (%) | Tumor stage at diagnosis (%) | Baseline PSA (ng/ml) median (range) | Follow-up time (month) Median (range) | |||||
Li H [14] | 2018 | China | Retrospective | Immunohistochemistry | First-line ADT | 168 | 71 (53–96) | ≤ 7 (35.7%) ≥ 8 (64.3%) | T1/T2 (9.5%) T3/T4 (67.9%) | 118.78 (2.61–4003.40) | 36 (IQR22–48) |
Saylor [22] | 2017 | USA | Retrospective | RNA ISH | First-line ADT | 22 | – | – | – | – | – |
Qu Y [15] | 2015 | China | Retrospective | IHC | First-line ADT | 104 | 70 (43–84) | ≤ 7 (44.2%) ≥ 8 (55.8%) | – | 122.5 (3.0–6006.2) | 25 (2–132) |
Guo Z [5] | 2009 | USA | Retrospective | IHC | Radical prostatectomy | 224 | – | 6–10 | – | – | – |